Systemic administration of a therapeutic preparation
Patent 5506203 Issued on April 9, 1996. Estimated Expiration Date: June 23, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.
Other References
Allenby et al., The Absorption of Insulin Across the Respiratory Tract of the Guinea-Pig (U), The Aerosol Society, Fourth Annual Conference 1990, pp. 129-134
Aungust and Rogers, Comparison of the Effects of Various Transmucosal Absorption Promotors on Buccal Insulin Delivery, Int. J. Pharm. (Netherlands), 1989, 53/3, 227-235
Bjork, Starch Microspheres as a Nasal Delivery System for Drugs, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 103, 1993
Bjork and Edman, Degradable Starch Microspheres as a Nasal Delivery System for Insulin, Int. J. Pharm. 47:233-238, 1988
Brange et al., Monomeric Insulins and Their Experimental and Clinical Implications, Diabetes Care 13:923-954, 1990
Edman and Bjork, Routes of Delivery: Case Studies, Advanced Drug Delivery Reviews 8:165-177, 1992
Igawa et al., Effect of Absorption Promoters in Intranasal Administration of Human Fibroblast Interferon as a Powder Dosage Form in Rabbits, Chem. Pharm. Bull. 37:418-421, 1989
Komada et al., Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung, J. Pharm. Sci. 83:863-867, 1994
Lasker, The Diabetes Control and Complications Trail, N. Engl. J. Med. 329:1035-1036, 1993
Laube et al., Preliminary Study of the Efficacy of Insulin Aerosol Delivery by Oral Inhalation in Diabetic Patients, JAMA 269:2106-2109, 1993
Lee et al., Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ratio, J. Pharm. Sci. 80:725-729, 1991
Mishima et al., Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats, J. Pharma -Dyn. 10:624-631, 1987
Morita et al., Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights, Biol. Pharm. Bull. 16:269:262, 1993
Nagai et al., Powder Dosage Form of Insulin for Nasal Administration, J. Controlled Release 1:15-22, 1984
"Diabetes Mellitus", Ch. VI in Scientific American Medicine, Scientific American, Inc., Apr. 1993
The Diabetes Control and Complications Trail Research Group, The Effect of Intensive Treatment of Diabetes on the Development . . . Complications in Insulin-Dependent Diabetes Mellitus, N. Engl. J. Med. 329:977-86, 1993
Pontiroli et al., Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: a Comparison of Powders and Spray Solutions and of Different Enhancing Agents, Eur. J. Clin. Pharmcol. 37:427-430, 1989
Schipper et al., Nasal Insulin Delivery with Dimethyl-ଲ-Cyclodextrin as an Absorption Enhancer in Rabbits: Powder More Effective than Liquid Formulations, Pharmaceutical Research 10:682-686, 1993
Selam and Charles, Devices for Insulin Administration, Diabetes Care 13:955-979, 1990
Touitou and Rubenstein, Targeted Enteral Delivery of Insulin to Rats, Int. J. Pharm. (Amst.), 30(2-3), 1986, 95-100
Wigley et al., Insulin Across Respiratory Mucosae by Aerosol Delivery, Diabetes 20:552-556, 1971
Zinman, Medical Intelligence--The Physiologic Replacement of Insulin, W. Engl. J. Med. 321:363-370, 198
June 23, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
